



IFW16

RAW SEQUENCE LISTING

DATE: 07/20/2006

PATENT APPLICATION: US/10/734,049C

TIME: 10:21:04

Input Set : A:\Q78382.APP

Output Set: N:\CRF4\07202006\J734049C.raw

3 <110> APPLICANT: ITOH, KYOGO
 4 SHICHIJO, SHIGEKI
 6 <120> TITLE OF INVENTION: TUMOR ANTIGEN
 8 <130> FILE REFERENCE: Q78382
 10 <140> CURRENT APPLICATION NUMBER: 10/734,049C
 11 <141> CURRENT FILING DATE: 2003-12-12
 13 <150> PRIOR APPLICATION NUMBER: PCT/JP02/05799
 14 <151> PRIOR FILING DATE: 2002-06-11
 16 <150> PRIOR APPLICATION NUMBER: JP 2001-177058
 17 <151> PRIOR FILING DATE: 2001-06-12
 19 <150> PRIOR APPLICATION NUMBER: JP 2001-250728
 20 <151> PRIOR FILING DATE: 2001-08-21
 22 <160> NUMBER OF SEQ ID NOS: 436
 24 <170> SOFTWARE: PatentIn Ver. 3.3
 26 <210> SEQ ID NO: 1
 27 <211> LENGTH: 9
 28 <212> TYPE: PRT
 29 <213> ORGANISM: Artificial Sequence
 31 <220> FEATURE:
 32 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 33 peptide recognized by HLA-A2 restricted cytotoxic
 34 T lymphocytes
 36 <400> SEQUENCE: 1
 37 Lys Leu Thr Gly Met Ala Phe Arg Val
 38 1 5
 41 <210> SEQ ID NO: 2
 42 <211> LENGTH: 10
 43 <212> TYPE: PRT
 44 <213> ORGANISM: Artificial Sequence
 46 <220> FEATURE:
 47 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 48 peptide recognized by HLA-A2 restricted cytotoxic
 49 T lymphocytes
 51 <400> SEQUENCE: 2
 52 Ala Leu Asn Asp His Phe Val Lys Leu Ile
 53 1 5 10
 56 <210> SEQ ID NO: 3
 57 <211> LENGTH: 9
 58 <212> TYPE: PRT
 59 <213> ORGANISM: Artificial Sequence
 61 <220> FEATURE:
 62 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 63 peptide recognized by HLA-A2 restricted cytotoxic

(Pg. 6)

RAW SEQUENCE LISTING

DATE: 07/20/2006

PATENT APPLICATION: US/10/734,049C

TIME: 10:21:04

Input Set : A:\Q78382.APP

Output Set: N:\CRF4\07202006\J734049C.raw

```

64      T lymphocytes
66 <400> SEQUENCE: 3
67 Ile Leu Gly Tyr Thr Glu His Gln Val
68   1               5
71 <210> SEQ ID NO: 4
72 <211> LENGTH: 10
73 <212> TYPE: PRT
74 <213> ORGANISM: Artificial Sequence
76 <220> FEATURE:
77 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
78     peptide recognized by HLA-A2 restricted cytotoxic
79     T lymphocytes
81 <400> SEQUENCE: 4
82 Gly Ile Val Glu Gly Leu Met Thr Thr Val
83   1               5               10
86 <210> SEQ ID NO: 5
87 <211> LENGTH: 10
88 <212> TYPE: PRT
89 <213> ORGANISM: Artificial Sequence
91 <220> FEATURE:
92 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
93     peptide recognized by HLA-A2 restricted cytotoxic
94     T lymphocytes
96 <400> SEQUENCE: 5
97 Thr Leu Leu Ala Gly Met Asn Lys Phe Leu
98   1               5               10
101 <210> SEQ ID NO: 6
102 <211> LENGTH: 10
103 <212> TYPE: PRT
104 <213> ORGANISM: Artificial Sequence
106 <220> FEATURE:
107 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
108     peptide recognized by HLA-A2 restricted cytotoxic
109     T lymphocytes
111 <400> SEQUENCE: 6
112 Thr Leu Ser Gly Gly Glu Leu Gln Arg Val
113   1               5               10
116 <210> SEQ ID NO: 7
117 <211> LENGTH: 9
118 <212> TYPE: PRT
119 <213> ORGANISM: Artificial Sequence
121 <220> FEATURE:
122 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
123     peptide recognized by HLA-A2 restricted cytotoxic
124     T lymphocytes
126 <400> SEQUENCE: 7
127 Ile Val Val Glu His Asp Leu Ser Val
128   1               5
131 <210> SEQ ID NO: 8

```

RAW SEQUENCE LISTING

DATE: 07/20/2006

PATENT APPLICATION: US/10/734,049C

TIME: 10:21:04

Input Set : A:\Q78382.APP

Output Set: N:\CRF4\07202006\J734049C.raw

```

132 <211> LENGTH: 10
133 <212> TYPE: PRT
134 <213> ORGANISM: Artificial Sequence
136 <220> FEATURE:
137 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
138     peptide recognized by HLA-A2 restricted cytotoxic
139     T lymphocytes
141 <400> SEQUENCE: 8
142 Ile Leu Thr Tyr Phe Arg Gly Ser Glu Leu
143   1             5             10
146 <210> SEQ ID NO: 9
147 <211> LENGTH: 10
148 <212> TYPE: PRT
149 <213> ORGANISM: Artificial Sequence
151 <220> FEATURE:
152 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
153     peptide recognized by HLA-A2 restricted cytotoxic
154     T lymphocytes
156 <400> SEQUENCE: 9
157 Ile Leu Ala Gly Lys Gln Lys Pro Asn Leu
158   1             5             10
161 <210> SEQ ID NO: 10
162 <211> LENGTH: 10
163 <212> TYPE: PRT
164 <213> ORGANISM: Artificial Sequence
166 <220> FEATURE:
167 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
168     peptide recognized by HLA-A2 restricted cytotoxic
169     T lymphocytes
171 <400> SEQUENCE: 10
172 Lys Glu Gly Glu Tyr Ile Lys Leu Lys Val
173   1             5             10
176 <210> SEQ ID NO: 11
177 <211> LENGTH: 10
178 <212> TYPE: PRT
179 <213> ORGANISM: Artificial Sequence
181 <220> FEATURE:
182 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
183     peptide recognized by HLA-A2 restricted cytotoxic
184     T lymphocytes
186 <400> SEQUENCE: 11
187 Ala Leu Gly Glu Glu Trp Lys Gly Tyr Val
188   1             5             10
191 <210> SEQ ID NO: 12
192 <211> LENGTH: 10
193 <212> TYPE: PRT
194 <213> ORGANISM: Artificial Sequence
196 <220> FEATURE:
197 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

```

RAW SEQUENCE LISTING

DATE: 07/20/2006

PATENT APPLICATION: US/10/734,049C

TIME: 10:21:04

Input Set : A:\Q78382.APP

Output Set: N:\CRF4\07202006\J734049C.raw

```

198      peptide recognized by HLA-A2 restricted cytotoxic
199      T lymphocytes
201 <400> SEQUENCE: 12
202 Asn Leu Ser Val Leu Asn Leu Val Ile Val
203   1           5           10
206 <210> SEQ ID NO: 13
207 <211> LENGTH: 9
208 <212> TYPE: PRT
209 <213> ORGANISM: Artificial Sequence
211 <220> FEATURE:
212 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
213      peptide recognized by HLA-A2 restricted cytotoxic
214      T lymphocytes
216 <400> SEQUENCE: 13
217 Val Leu Thr His Gly Arg Val Arg Leu
218   1           5
221 <210> SEQ ID NO: 14
222 <211> LENGTH: 10
223 <212> TYPE: PRT
224 <213> ORGANISM: Artificial Sequence
226 <220> FEATURE:
227 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
228      peptide recognized by HLA-A2 restricted cytotoxic
229      T lymphocytes
231 <400> SEQUENCE: 14
232 Lys Ile Gln Arg Leu Val Thr Pro Arg Val
233   1           5           10
236 <210> SEQ ID NO: 15
237 <211> LENGTH: 9
238 <212> TYPE: PRT
239 <213> ORGANISM: Artificial Sequence
241 <220> FEATURE:
242 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
243      peptide recognized by HLA-A2 restricted cytotoxic
244      T lymphocytes
246 <400> SEQUENCE: 15
247 Val Gln Phe Val Gln Gly Ile Phe Val
248   1           5
251 <210> SEQ ID NO: 16
252 <211> LENGTH: 9
253 <212> TYPE: PRT
254 <213> ORGANISM: Artificial Sequence
256 <220> FEATURE:
257 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
258      peptide recognized by HLA-A2 restricted cytotoxic
259      T lymphocytes
261 <400> SEQUENCE: 16
262 Lys Ser Ala Leu Thr Val Gln Phe Val
263   1           5

```

RAW SEQUENCE LISTING

DATE: 07/20/2006

PATENT APPLICATION: US/10/734,049C

TIME: 10:21:04

Input Set : A:\Q78382.APP

Output Set: N:\CRF4\07202006\J734049C.raw

```

266 <210> SEQ ID NO: 17
267 <211> LENGTH: 10
268 <212> TYPE: PRT
269 <213> ORGANISM: Artificial Sequence
271 <220> FEATURE:
272 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
273     peptide recognized by HLA-A2 restricted cytotoxic
274     T lymphocytes
276 <400> SEQUENCE: 17
277 Ile Met Asn Gln Glu Lys Leu Ala Lys Leu
278   1             5             10
281 <210> SEQ ID NO: 18
282 <211> LENGTH: 10
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
288     peptide recognized by HLA-A2 restricted cytotoxic
289     T lymphocytes
291 <400> SEQUENCE: 18
292 Leu Gln Phe Ser Leu Lys Lys Leu Gly Val
293   1             5             10
296 <210> SEQ ID NO: 19
297 <211> LENGTH: 9
298 <212> TYPE: PRT
299 <213> ORGANISM: Artificial Sequence
301 <220> FEATURE:
302 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
303     peptide recognized by HLA-A2 restricted cytotoxic
304     T lymphocytes
306 <400> SEQUENCE: 19
307 Asn Met Phe Thr Asn Gln Gly Thr Val
308   1             5
311 <210> SEQ ID NO: 20
312 <211> LENGTH: 10
313 <212> TYPE: PRT
314 <213> ORGANISM: Artificial Sequence
316 <220> FEATURE:
317 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
318     peptide recognized by HLA-A2 restricted cytotoxic
319     T lymphocytes
321 <400> SEQUENCE: 20
322 Arg Leu His Asn Asp Arg Val Tyr Tyr Val
323   1             5             10
326 <210> SEQ ID NO: 21
327 <211> LENGTH: 10
328 <212> TYPE: PRT
329 <213> ORGANISM: Artificial Sequence
331 <220> FEATURE:

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/734,049C

DATE: 07/20/2006
TIME: 10:21:05

Input Set : A:\Q78382.APP
Output Set: N:\CRF4\07202006\J734049C.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:284; Xaa Pos. 80

Seq#:343; N Pos. 2578

Seq#:352; N Pos. 1332

VERIFICATION SUMMARY

DATE: 07/20/2006

PATENT APPLICATION: US/10/734,049C

TIME: 10:21:05

Input Set : A:\Q78382.APP

Output Set: N:\CRF4\07202006\J734049C.raw

L:6785 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:284 after pos.:64
L:8898 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:343 after pos.:2520
L:9177 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:352 after pos.:1320